SHANDONG JINCHENG PHARMACEUTICAL GROUP CO., LTD

Shandong Jincheng Pharmaceutical Group Co., Ltd

300233

CNE100001500

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
16.21 ^CNY	+3.78%		+6.57%	-2.70%

Apr. 24	Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 29	Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023	CI

Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback announced on April 29, 2021, has closed with 3,536,400 shares, representing 0.9% for CNY 80 million.

May 19, 2021

The company closed its plan on May 20, 2021.

Latest news about Shandong Jincheng Pharmaceutical Group Co., Ltd

Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for the Year 2023	Mar. 28	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Tranche Update on Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback Plan announced on February 2, 2024.	Feb. 08	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd's Equity Buyback announced on February 2, 2024, has closed with 4,543,000 shares, representing 1.18% for CNY 55 million.	Feb. 07	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd announces an Equity Buyback for CNY 70 million worth of its shares.	Feb. 02	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd authorizes a Buyback Plan.	Feb. 01	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-24	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-18	CI
Jincheng Pharmaceutical Gets License to Produce E-Cigarette Nicotine	23-07-17	MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Directorate Appointments	23-04-24	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Cash Dividend for the Year 2022	23-04-24	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Proposes Final Cash Dividend for 2022	23-03-31	CI
Three Jincheng Pharmaceutical Medicines Shortlisted For China’s Drug Procurement Program	23-03-29	MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-24	CI
Jincheng Pharma Secures China's First License to Produce E-Cigarettes; Shares Slide 5%	22-06-15	MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Announces Final Profit Distribution Plan for 2021, Payable on May 11, 2022	22-04-28	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Approves Profit Distribution for the Year 2021	22-04-19	CI
Shandong Jincheng Pharma Maintains Final Dividend After Swinging to Profit in 2021	22-03-27	MT
Shandong Jincheng Pharmaceutical Group Co., Ltd Announces the Profit Distribution Proposal for the Year 2021	22-03-25	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
Shandong Jincheng Pharmaceutical Group Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI

Chart Shandong Jincheng Pharmaceutical Group Co., Ltd

Duration

Period

Chart Shandong Jincheng Pharmaceutical Group Co., Ltd

More charts

Shandong Jincheng Pharmaceutical Group Co., Ltd., formerly Shandong Jincheng Pharmaceutical Co., Ltd., is a China-based company principally engaged in the research, development, production and sale of cephems medicine intermediates. The Company mainly provides active ester side chain of cephalosporin products, other pharmaceutical chemical products, as well as bio-pharmaceuticals and specialty active pharmaceutical ingredient (API). The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SHANDONG JINCHENG PHARMACEUTICAL GROUP CO., LTD	-2.70%	859M
NOVO NORDISK A/S	+25.01%	556B
JOHNSON & JOHNSON	-6.33%	354B
MERCK & CO., INC.	+19.90%	331B
ABBVIE INC.	+7.95%	296B
ASTRAZENECA PLC	+13.70%	233B
NOVARTIS AG	+5.87%	201B
ROCHE HOLDING AG	-9.90%	193B
PFIZER, INC.	-12.26%	143B
AMGEN INC.	-6.47%	144B

Other Pharmaceuticals